USO 23335
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)
Disease Types: Melanoma Research
Available at:
- Norfolk (Brock Cancer Center)
- Chesapeake
- Hampton (CarePlex)
- Newport News (Port Warwick III)
- Virginia Beach (Princess Anne)
- Williamsburg